Helus Pharma Inc. (NEO:HELP)
Canada · Delayed Price · Currency is CAD | Market Cap | 922.86M +120.1% |
| Revenue (ttm) | n/a |
| Net Income | -243.13M |
| EPS | -5.72 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,621 |
| Open | 12.00 |
| Previous Close | 11.86 |
| Day's Range | 12.00 - 12.90 |
| 52-Week Range | 5.30 - 20.88 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Helus Pharma
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’s preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strat... [Read more]
News
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT
Helus Pharma co-founders step down from executive roles, Lawson named chair
Helus Pharma (HELP) announced that co-founders Eric So and Paul Glavine have stepped down from their respective executive and consulting roles while continuing to serve as members of the board…
Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development
Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effe...
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2
Helus Pharma Transcript: Study update
HLP003 Phase III APPROACH results are expected later in Q4 2026, with EMBRACE ongoing and EXTEND evaluating durability and redosing. A 30 mg HLP004 Phase II GAD study is planned to start in Q1 2027.
Helus Pharma Press release: Study update
Helus Pharma issued a press release on October 21, 2026, disclosing material business information to investors.
Helus Pharma Slides: Study update
Helus Pharma has posted slides in relation to its latest quarterly earnings report, which was published on October 21, 2026.
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 20...
Helus Pharma Slides: Corporate presentation
Helus Pharma has posted slides in relation to its latest quarterly earnings report, which was published on October 8, 2026.
Helus Pharma to Host Investor Presentation on October 21, 2026
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds ...
Helus Pharma announces completion of legal name change
Helus Pharma (HELP) announces the Company’s legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at…
Helus Pharma Announces Completion of Legal Name Change
NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal ...
Helus Pharma Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
The summit highlighted late-stage development of deuterated psilocin for adjunctive MDD, with a phase III readout expected in Q4 2026 and NDA filing in 2028. The program aims for strong efficacy, durability, and safety advantages over current adjunctive therapies.
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developin...
Helus Pharma Transcript: AGM 2026
The AGM covered financial results, auditor appointment, board elections, and a special resolution to change the company name. All voting was conducted virtually, with results to be published post-meeting.
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT
Helus Pharma presents new analyses on HLP003 in MDD
Helus Pharma (HELP) announced the presentation of four posters evaluating HLP003 at Psych Congress 2026, September 15-19, 2026, at the Ernest Morial Convention Center in New Orleans, Louisiana. Three ...
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK ...
Helus Pharma selloff Friday a buying opportunity, says Barclays
Barclays views the selloff Friday in shares of Helus Pharma (HELP) as a buying opportunity. The firm initiated the stock on Friday morning with an Overweight rating and $35 price…
Helus Pharma initiated with an Overweight at Barclays
Barclays initiated coverage of Helus Pharma (HELP) with an Overweight rating and $35 price target
Helus Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing a late-stage program for adjunctive MDD with phase III data expected in Q4, supported by strong phase II results and FDA breakthrough designation. Additional programs target anxiety and early-stage mental health indications, with a focus on execution and scalable growth. The sector is seeing increased validation and interest from large pharma.
Helus Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is advancing a robust neuropsychiatry pipeline, with lead candidate HLP003 in phase III for adjunctive MDD and top-line data expected in Q4 2026. Strong phase II results, a supportive regulatory environment, and a solid financial position underpin plans for NDA filing and potential approval in 2028.
Helus Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Leadership highlighted deep CNS and psychiatry expertise, with a focus on novel serotonergic agonists for mental health. CYB-003 is in phase III for adjunctive MDD, with top-line data due Q4 and NDA filing targeted for 2028. CYB-004 advances in anxiety, and infrastructure is scaling for commercialization.
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT. CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:3...
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. ...